Ann Rhoads, an experienced financial executive, has been appointed to the board of directors of iTeos Therapeutics SA, a Belgium-based immuno-oncology company. Ms Rhoads most recently served as chief financial officer at Forty Seven Inc, a clinical stage oncology company that was acquired by Gilead Sciences Inc in April. Prior to this, she was CFO at Zogenix Inc, a company developing medicines for rare diseases. Ms Rhoads holds a master of business administration from the Harvard Business School and a bachelor of science from the University of Arkansas, both in the US.
iTeos Therapeutics announced the appointment on 1 June 2020.
Copyright 2020 Evernow Publishing Ltd.